About this episode
Poolbeg Pharma (AIM: POLB) has announced that its lead asset, POLB 001, will play a central role in the new RISE research programme, a groundbreaking initiative tackling cytokine release syndrome (CRS) caused by cancer immunotherapy. In this interview, CEO Jeremy Skillington and Scientific Advisor Liam Loughrey explain what this means for the company, how the collaboration with leading academic and medical institutions came about, and what the implications are for patients and shareholders alike.
Get every episode summarized
Each time The Vox Markets Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Vox Markets Podcast
2369: Poolbeg hits significant milestone with POLB 001
The Vox Markets Podcast
Apr 15, 20266:18failed
2368: hVIVO FY25 Results: Growth, Acquisitions and What Comes Next in 2026
The Vox Markets Podcast
Apr 15, 20268:41failed
2367: Quantum Data Energy CEO on Q1 Progress
The Vox Markets Podcast
Apr 15, 202611:52failed
2366: Chancery Royalty gets set for US$7,000 gold
The Vox Markets Podcast
Apr 14, 202613:58failed